People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Other, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biolog, Inc. /DE/ | — | Biotechnology | Series B | $33.6M | $88.3M | 2025 |
| Flagship Biosciences, Inc. | — | Biotechnology | Series B | $26.8M | $39.2M | 2023 |
| Optofluidics, Inc. | — | Biotechnology | Series A | $19.4M | $96.6M | 2020 |
| BioInformatics, Inc. | — | Other | Series A | $11.2M | $90.8M | 2018 |
| LTS1, Inc. | — | Other | Series A | $10.0M | $14.2M | 2023 |
| Cellaria, Inc. | — | Other | Pre-Seed | $1.6M | $1.8M | 2019 |
| Empire Genomics Corp. | — | Biotech | Pre-Seed | $500K | $16.7M | 2021 |
William Snider at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Snider on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chad Souvignier | 2 | 4 |
| Robert Wicke | 2 | 2 |
| Mark Anderson | 1 | 20 |
| David Weber | 1 | 8 |
| Joseph D. Keegan | 1 | 4 |
| Joseph Keegan | 1 | 4 |
| Paul McEwan | 1 | 3 |
| Tim Johnson | 1 | 3 |
| Christopher McGuinness | 1 | 3 |
| Casey McGlynn | 1 | 3 |
| Aaron Fisher | 1 | 3 |
| Tim Harkness | 1 | 3 |
| Bryan Poltilove | 1 | 3 |
| Shahram Hejazi | 1 | 3 |
| David Mullarkey | 1 | 2 |
| ROBERT HART | 1 | 2 |
| Trevor Johnson | 1 | 2 |
| Bill D. Snider | 1 | 1 |
| Jason D. Novi | 1 | 1 |
| Tim D. Harkness | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.